Risk Factors for Mortality in COVID-19 Hospitalized Patients in Piedmont, Italy: Results from the Multicenter, Regional, CORACLE Registry

• Published in: Journal of clinical medicine Vol. 10; no. 9; p. 1951
• Main Authors: De Rosa, Francesco Giuseppe, Palazzo, Annagloria, Rosso, Tiziana, Shbaklo, Nour, Mussa, Marco, Boglione, Lucio, Borgogno, Enrica, Rossati, Antonella, Mornese Pinna, Simone, Scabini, Silvia, Chichino, Guido, Borrè, Silvio, Del Bono, Valerio, Garavelli, Pietro Luigi, Barillà, Diego, Cattel, Francesco, Di Perri, Giovanni, Ciccone, Giovannino, Lupia, Tommaso, Corcione, Silvia
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01-05-2021; MDPI
• Subjects: Clinical medicine; Coronaviruses; COVID-19; Epidemiology; Mortality; Risk factors; Italy; COVID-19; mortality; hydroxichloroquine; SARS-CoV-2; pneumonia
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm10091951

CORACLE is a retrospective and prospective, regional multicenter registry, developed to evaluate risk factors for mortality in a cohort of patients admitted with SARS-CoV-2 infection within non-intensive wards.
The primary objective was to estimate the role of several prognostic factors on hospital mortality in terms of adjusted Odds Ratios (aOR) with multivariable logistic regression models.
A total of 1538 patients were enrolled; 42% were female, and 58% were >70 years old. Deceased patients were 422 (27%), with a median age of 83 years (IQR (Inter Quartile Range) 76-87). Older age at admission (aOR 1.07 per year, 95%CI 1.06-1.09), diabetes (1.41, 1.02-1.94), cardiovascular disease (1.79, 1.31-2.44), immunosuppression (1.65, 1.04-2.62), estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m
(3.53, 2.26-5.51), higher C-reactive protein values and a decreased PaO
/FiO
ratio at admission were associated with a higher risk of hospital mortality. Amongst patients still alive on day 7, only hydroxychloroquine (HCQ) treatment was associated with reduced mortality (0.57, 0.36-0.90).
Several risk factors were associated with mortality in SARS-CoV-2 positive patients. Although HCQ seems to be the only factor significantly associated with reduced mortality, this result is in contrast with evidence from randomized studies. These results should be interpreted in light of the study limitations.